
The UroOnc Minute: Neoadjuvant Therapy Before Radical Prostatectomy, With Isaac Y. Kim, MD, PhD, MBA
Isaac Y. Kim, MD, PhD, MBA, joins to discuss the evolving data surrounding neoadjuvant therapy before radical prostatectomy in prostate cancer.
The FDA has approved the first generic versions of the antibiotic levofloxacin.
The FDA has approved the first generic versions of the antibiotic levofloxacin.
Levofloxacin is indicated for the treatment of mild, moderate, or severe bacterial infections of the kidneys, bladder, prostate, skin, and sinuses caused by specific germs.
Generic tablet, oral solution, and injectable solution dosage forms of levofloxacin have been approved. The approval includes applications for generic levofloxacin submitted by 12 manufacturers.





